Contrast agents as a biological marker in magnetic resonance imaging of the liver: Conventional and new approaches

Abdominal Imaging

Volumn 37, Issue 2, 2012, Pages 164-179

  Sommer, Wieland H ^a   Sourbron, Steven ^b   Huppertz, Alexander ^c   Ingrisch, Michael ^a   Reiser, Maximilian F ^a   Zech, Christoph J ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Contrast agents; Dynamic contrast enhanced MRI; Hepatobiliary contrast agents; Liver MRI; Perfusion MRI

Indexed keywords

BIOLOGICAL MARKER; CONTRAST MEDIUM; FERUCARBOTRAN; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOXETIC ACID; MANGAFODIPIR; SUPERPARAMAGNETIC IRON OXIDE;

ARTICLE; CONTRAST ENHANCEMENT; DATA PROCESSING; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DRUG UPTAKE; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; ELASTOGRAPHY; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; LIVER METASTASIS; LIVER PERFUSION; LIVER TRANSPLANTATION; MAGNETIC RESONANCE ANGIOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFUSION WEIGHTED IMAGING; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; THREE DIMENSIONAL IMAGING; TISSUE SPECIFICITY; TREATMENT RESPONSE;

BIOLOGICAL MARKERS; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LIVER DISEASES; MAGNETIC RESONANCE IMAGING;

EID: 84863726765     PISSN: 09428925     EISSN: 14320509     Source Type: Journal    
DOI: 10.1007/s00261-011-9734-9     Document Type: Article

References (88)

1. Shellock FG (1999) Safety of MRI contrast agents. JMRI 10:477-484
2. Oudkerk M, Sijens PE, van Beek EJ, Kuijpers TJ (1995) Safety and efficacy of dotarem (Gd-DOTA) versus magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system. Invest Radiol 30:75-78
3. Tombach B, Benner T, Reimer P, et al. (2003) Do highly concentrated gadolinium chelates improve MR brain perfusion imaging? Intraindividually controlled randomized crossover concentration comparison study of 0.5 versus 1.0 mol/L gadobutrol. Radiology 226:880-888 (Pubitemid 36259167)
4. Chambon C, Clement O, Blanche RL, et al. (1993) Superparamagnetic iron oxides as positive MR contrast agents: in vitro and in vivo evidence. Magn Reson Imaging 11:509-519
5. Zech CJ, Namkung S, Helmberger T, Reiser MF, Schoenberg SO (2005) Efficacy of ferucarbotran-enhanced early dynamic MR imaging with T1-weighted sequences for characterization of focal liver lesions. Eur Radiol 15(suppl 3):37
6. Ba-Ssalamah A, Heinz-Peer G, Schima W, et al. (2000) Detection of focal hepatic lesions: comparison of unenhanced and SHU 555 A-enhanced MR imaging versus biphasic helical CTAP. J Magn Reson Imaging 11:665-672 (Pubitemid 30350310)
7. Vogl TJ, Schwarz W, Blume S, et al. (2003) Preoperative evaluation of malignant liver tumors: comparison of unenhanced and SPIO (Resovist)-enhanced MR imaging with biphasic CTAP and intraoperative US. Eur Radiol 13:262-272 (Pubitemid 36798602)
8. Ward J, Guthrie JA, Scott DJ, et al. (2000) Hepatocellular carcinoma in the cirrhotic liver: double-contrast MR imaging for diagnosis. Radiology 216:154-162 (Pubitemid 30434736)
9. Namkung S, Zech CJ, Helmberger T, Reiser MF, Schoenberg SO (2007) Superparamagnetic iron oxide (SPIO)-enhanced liver MRI with ferucarbotran: efficacy for characterization of focal liver lesions. J Magn Reson Imaging 25:755-765 (Pubitemid 46516728)
10. Zech CJ, Herrmann KA, Huber A, et al. (2004) High-resolutionMRimaging of the liver with T2-weighted sequences using integrated parallel imaging: comparison of prospective motion correction and respiratory triggering. J Magn Reson Imaging 20:443-450 (Pubitemid 39121943)
11. Huppertz A, Balzer T, Blakeborough A, et al. (2004) Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology 230:266-275 (Pubitemid 37549812)
12. Petersein J, Spinazzi A, Giovagnoni A, et al. (2000) Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging-a multicenter phase III clinical study. Radiology 215:727-736 (Pubitemid 30346007)
13. Huppertz A, Haraida S, Kraus A, et al. (2005) Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT-initial observations. Radiology 234:468-478 (Pubitemid 40139918)
14. Zech CJ, Grazioli L, Breuer J, Reiser MF, Schoenberg SO (2008) Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trial. Invest Radiol 43:504-511
15. Malone D, Zech CJ, Ayuso C, et al. (2008) Magnetic resonance imaging of the liver: consensus statement from the 1st International Primovist User Meeting. Eur Radiol 18(Suppl 4):849-864
16. Zech CJ, Vos B, Nordell A, et al. (2009) Vascular enhancement in early dynamic liver MR imaging in an animal model: comparison of two injection regimen and two different doses Gd-EOB-DTPA (gadoxetic acid) with standard Gd-DTPA. Invest Radiol 44:305-310
17. Bartolozzi C, Donati F, Cioni D, et al. (2004) Detection of colorectal liver metastases: a prospective multicenter trial comparing unenhanced MRI, MnDPDP-enhanced MRI, and spiral CT. Eur Radiol 14:14-20 (Pubitemid 38181050)
18. Gehl HB, Bourne M, Grazioli L, Moller A, Lodemann KP (2001) Off-site evaluation of liver lesion detection by Gd-BOPTA-enhanced MR imaging. Eur Radiol 11:187-192 (Pubitemid 32755434)
19. Kim YK, Lee JM, Kim CS, et al. (2005) Detection of liver metastases: gadobenate dimeglumine-enhanced three-dimensional dynamic phases and one-hour delayed phase MR imaging versus superparamagnetic iron oxide-enhanced MR imaging. Eur Radiol 15:220-228
20. Grazioli L, Morana G, Federle MP, et al. (2001) Focal nodular hyperplasia: morphologic and functional information from MR imaging with gadobenate dimeglumine. Radiology 221:731-739 (Pubitemid 33101765)
21. Grazioli L, Morana G, Kirchin MA, Schneider G (2005) Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology 236:166-177 (Pubitemid 40853309)
22. Zech CJ, Herrmann KA, Reiser MF, Schoenberg SO (2007) MR imaging in patients with suspected liver metastases: value of liverspecific contrast agent Gd-EOB-DTPA. Magn Reson Med Sci 6:43-52
23. Del Frate C, Bazzocchi M, Mortele KJ, et al. (2002) Detection of liver metastases: comparison of gadobenate dimeglumine-enhanced and ferumoxides-enhanced MR imaging examinations. Radiology 225:766-772 (Pubitemid 35387115)
24. Burrel M, Llovet JM, Ayuso C, et al. (2003) MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 38:1034-1042 (Pubitemid 37221687)
25. Lauenstein TC, Salman K, Morreira R, et al. (2007) Gadoliniumenhanced MRI for tumor surveillance before liver transplantation: center-based experience. AJR Am J Roentgenol 189:663-670 (Pubitemid 47328550)
26. Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases (2005) Management of hepatocellular carcinoma. Hepatology 42:1208-1236 (Pubitemid 43112690)
27. Zech CJ, Reiser MF, Herrmann KA (2009) Imaging of hepatocellular carcinoma by computed tomography and magnetic resonance imaging: state of the art. Dig Dis 27:114-124
28. Bhartia B, Ward J, Guthrie JA, Robinson PJ (2003) Hepatocellular carcinoma in cirrhotic livers: double-contrast thin-section MR imaging with pathologic correlation of explanted tissue. AJR 180:577-584 (Pubitemid 36237194)
29. Imai Y, Murakami T, Yoshida S, et al. (2000) Superparamagnetic iron oxide-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading. Hepatology 32:205-212 (Pubitemid 30614651)
30. Kwak HS, Lee JM, Kim CS (2004) Preoperative detection of hepatocellular carcinoma: comparison of combined contrast-enhanced MR imaging and combined CT during arterial portography and CT hepatic arteriography. Eur Radiol 14:447-457
31. Kim YK, Kim CS, Kwak HS, Lee JM (2004) Three-dimensional dynamic liver MR imaging using sensitivity encoding for detection of hepatocellular carcinomas: comparison with superparamagnetic iron oxide-enhanced mr imaging. J Magn Reson Imaging 20:826-837 (Pubitemid 39426079)
32. Choi SH, Lee JM, Yu NC, et al. (2008) Hepatocellular carcinoma in liver transplantation candidates: detection with gadobenate dimeglumine- enhanced MRI. Am J Roentgenol 191:529-536
33. Kim YK, Kim CS, Han YM, et al. (2009) Detection of hepatocellular carcinoma: gadoxetic acid-enhanced 3-dimensional magnetic resonance imaging versus multi-detector row computed tomography. J Comput Assist Tomogr 33:844-850
34. Kim SH, Kim SH, Lee J, et al. (2009) Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol 192:1675-1681
35. Ahn SS, Kim MJ, Lim JS, et al. (2010) Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 255:459-466
36. Lee JM, Kim SB, Lee JY, et al. (2008) Enhancement patterns on gadoxetic acid-enhanced MR imaging of hepatocellular carcinoma in the cirrhotic liver: comparison with multiphasic liver CT. 6th International Meeting Hepatocellular Carcinoma: Eastern and Western Experiences, p 19
37. Kim JI, Lee JM, Choi JY, et al. (2008) The value of gadobenate dimeglumine-enhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver. Invest Radiol 43:202-210 (Pubitemid 351643147)
38. Martí-Bonmatí L (1997) MR imaging characteristics of hepatic tumors. Eur Radiol 7:249-258 (Pubitemid 127538591)
39. Do RKG, Rusinek H, Taouli B (2009) Dynamic contrast-enhanced MR imaging of the liver: current status and future directions. Magn Reson Imaging Clin N Am 17:339-349
40. Pandharipande PV, Krinsky GA, Rusinek H, Lee VS (2005) Perfusion imaging of the liver: current challenges and future goals. Radiology 234:661-673 (Pubitemid 40250807)
41. Jarnagin WR, Schwartz LH, Gultekin DH, et al. (2009) Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann Oncol 20:1589-1595
42. Chan NK, Obenaus A, Tan A, et al. (2009) Monitoring neovascularization of intraportal islet grafts by dynamic contrast enhanced magnetic resonance imaging. Islets 1:249-255
43. Mross K, Fasol U, Frost A, et al. (2009) DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study. J Angiogenes Res 1:5
44. Ng CS, Raunig DL, Jackson EF, et al. (2010) Reproducibility of perfusion parameters in dynamic contrast-enhanced MRI of lung and liver tumors: effect on estimates of patient sample size in clinical trials and on individual patient responses. AJR Am J Roentgenol 194:W134-W140
45. Baxter S, Wang ZJ, Joe BN, et al. (2009) Timing bolus dynamic contrast-enhanced (DCE) MRI assessment of hepatic perfusion: Initial experience. J Magn Reson Imaging 29:1317-1322
46. Cuenod CA, Leconte I, Siauve N, et al. (2002) Deconvolution technique for measuring tissue perfusion by dynamic CT: application to normal and metastatic liver. Acad Radiol 9(suppl 1):S205-S211 (Pubitemid 34441482)
47. Materne R, Smith AM, Peeters F, et al. (2002) Assessment of hepatic perfusion parameters with dynamic MRI. Magn Reson Med 47:135-142 (Pubitemid 34019702)
48. Sourbron S, Sommer W, Zech CJ, Reiser MF, Herrmann K (2010) Tracer-kinetic analysis of Gd-EOB-DTPA in the liver with a dualinlet two-compartment uptake model. In: Proceedings of the International Society for Magnetic Resonance in Medicine
49. Brix G, Ziegler SI, Bellemann ME, et al. (2001) Quantification of [18F]FDG uptake in the normal liver using dynamic PET: impact and modeling of the dual hepatic blood supply. J Nucl Med 42:1265-1273 (Pubitemid 32717848)
50. Michoux N, Huwart L, Abarca-Quinones J, et al. (2008) Transvascular and interstitial transport in rat hepatocellular carcinomas: dynamic contrastenhanced MRI assessment with low- and highmolecular weight agents. J Magn Reson Imaging 28:906-914
51. Vriens D, van Laarhoven HWM, van Asten JA, et al. (2009) Chemotherapy response monitoring of colorectal liver metastases by dynamic Gd-DTPA-enhanced MRI perfusion parameters and 18F-FDG PET metabolic rate. J Nucl Med 50:1777-1784
52. Nilsson H, Nordell A, Vargas R, et al. (2009) Assessment of hepatic extraction fraction and input relative blood flow using dynamic hepatocyte-specific contrast-enhanced MRI. J Magn Reson Imaging 29:1323-1331
53. Orton MR, Miyazaki K, Koh DM, et al. (2009) Optimizing functional parameter accuracy for breath-hold DCE-MRI of liver tumours. Phys Med Biol 54:2197-2215
54. Scharf J, Zapletal C, Hess T, et al. (1999) Assessment of hepatic perfusion in pigs by pharmacokinetic analysis of dynamic MR images. J Magn Reson Imaging 9:568-572 (Pubitemid 29194296)
55. Scharf J, Kemmling A, Hess T, et al. (2007) Assessment of hepatic perfusion in transplanted livers by pharmacokinetic analysis of dynamic magnetic resonance measurements. Invest Radiol 42:224-229 (Pubitemid 46398860)
56. Hagiwara M, Rusinek H, Lee VS, et al. (2008) Advanced liver fibrosis: diagnosis with 3D whole-liver perfusion MR imaging- initial experience. Radiology 246:926-934
57. Koh TS, Thng CH, Hartono S, et al. (2009) Dynamic contrastenhanced CT imaging of hepatocellular carcinoma in cirrhosis: feasibility of a prolonged dual-phase imaging protocol with tracer kinetics modeling. Eur Radiol 19:1184-1196
58. Koh TS, Thng CA, Lee PS, et al. (2008) Hepatic metastases: in vivo assessment of perfusion parameters at dynamic contrast-enhanced MR imaging with dual-input two-compartment tracer kinetics model. Radiology 249:307-320
59. Mescam M, Kretowski M, Bezy-Wendling J (2010) Multiscale model of liver DCE-MRI towards a better understanding of tumor complexity. IEEE Trans Med Imaging 29:699-707
60. White MJ, O'Gorman RL, Charles-Edwards EM, et al. (2007) Parametric mapping of the hepatic perfusion index with gadolinium- enhanced volumetric MRI. Br J Radiol 80:113-120 (Pubitemid 46951254)
61. Schlemmer M, Sourbron SP, Schinwald N, et al. (2011) Perfusion patterns of metastatic gastrointestinal stromal tumor lesions under specific molecular therapy. Eur J Radiol 77(2):312-318
62. Pettigrew RI, Avruch L, Dannels W, Coumans J, Bernardino ME (1986) Fast-field-echo MR imaging with Gd-DTPA: physiologic evaluation of the kidney and liver. Radiology 160:561-563 (Pubitemid 16070679)
63. Peeters F, Annet L, Hermoye L, Van Beers BE (2004) Inflow correction of hepatic perfusion measurements using T1-weighted, fast gradient-echo, contrast-enhanced MRI. Magn Reson Med 51:710-717 (Pubitemid 38420447)
64. Song T, Laine AF, Chen Q, et al. (2009) Optimal k-space sampling for dynamic contrast-enhanced MRI with an application to MR renography. Magn Reson Med 61:1242-1248
65. Song T, Lee V, Rusinek H, Kaur M, Laine A (2005) Automatic 4-D registration in dynamic MR renography. Conf Proc IEEE Eng Med Biol Soc 3:3067-3070 (Pubitemid 46229571)
66. Mainardi LT, Passera KM, Lucesoli A, et al. (2006) A method for dynamic subtraction MR imaging of the liver. BMC Med Imaging 6:5
67. Bokacheva L, Rusinek H, Chen Q, et al. (2007) Quantitative determination of Gd-DTPA concentration in T1-weighted MR renography studies. Magn Reson Med 57:1012-1018 (Pubitemid 46915356)
68. Noterdaeme O, Brady M (2008) Contrast enhanced magnetic resonance imaging of the liver. Conf Proc IEEE Eng Med Biol Soc 2008:831-834
69. Provenzale JM (2007) Imaging of angiogenesis: clinical techniques and novel imaging methods. AJR Am J Roentgenol 188:11-23 (Pubitemid 46012485)
70. Faria SC, Ganesan K, Mwangi I, et al. (2009) MR imaging of liver fibrosis: current state of the art. Radiographics 29:1615-1635
71. Alisi A, Pinzani M, Nobili V (2009) Diagnostic power of fibroscan in predicting liver fibrosis in nonalcoholic fatty liver disease. Hepatology 50:2048-2049
72. Sandrasegaran K, Akisik FM, Lin C, et al. (2009) Value of diffusion- weighted MRI for assessing liver fibrosis and cirrhosis. AJR Am J Roentgenol 193:1556-1560
73. Tatsumi C, Kudo M, Ueshima K, et al. (2010) Non-invasive evaluation of hepatic fibrosis for type C chronic hepatitis. Intervirology 53:76-81
74. Castera L, Foucher J, Bernard PH, et al. (2010) Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 51:828-835
75. Annet L, Materne R, Danse E, et al. (2003) Hepatic flow parameters measured with MR imaging and Doppler US: correlations with degree of cirrhosis and portal hypertension. Radiology 229:409-414 (Pubitemid 37310826)
76. van Beers BE, Materne R, Annet L, et al. (2003) Capillarization of the sinusoids in liver fibrosis: noninvasive assessment with contrastenhanced MRI in the rabbit. Magn Reson Med 49:692-699 (Pubitemid 36389979)
77. Martinez-Hernandez A (1985) The hepatic extracellular matrix. II. Electron immunohistochemical studies in rats with CCl4-induced cirrhosis. Lab Invest 53:166-186 (Pubitemid 15049008)
78. Turetschek K, Schima W, Stift A, et al. (1997) Diagnostic imaging after liver transplantation. Radiology 37:197-204
79. Shimamura T, Saito S, Morita K, et al. (2000) Detection of vascular endothelial growth factor and its receptor expression in human hepatocellular carcinoma biopsy specimens. J Gastroenterol Hepatol 15:640-646 (Pubitemid 30435715)
80. Terayama N, Terada T, Nakanuma Y (1996) An immunohistochemical study of tumour vessels in metastatic liver cancers and the surrounding liver tissue. Histopathology 29:37-43 (Pubitemid 26232520)
81. Abou-Alfa GK, Schwartz L, Ricci S, et al. (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293-4300 (Pubitemid 46630787)
82. Alberts SR, Wagman LD (2008) Chemotherapy for colorectal cancer liver metastases. Oncologist 13:1063-1073
83. El Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557-2576 (Pubitemid 46890874)
84. Sahani DV, Holalkere NS, Mueller PR, Zhu AX (2007) Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue- initial experience. Radiology 243:736-743 (Pubitemid 46799427)
85. Tsushima Y, Blomley MJ, Yokoyama H, Kusano S, Endo K (2001) Does the presence of distant and local malignancy alter parenchymal perfusion in apparently disease-free areas of the liver? Dig Dis Sci 46:2113-2119 (Pubitemid 32955219)
86. Thng CH, Koh TS, Collins DJ, Koh DM (2010) Perfusion magnetic resonance imaging of the liver. World J Gastroenterol 16:1598-1609
87. Cuenod C, Leconte I, Siauve N, et al. (2001) Early changes in liver perfusion caused by occult metastases in rats: detection with quantitative CT. Radiology 218:556-561 (Pubitemid 32121075)
88. Morgan B, Thomas AL, Drevs J, et al. (2003) Dynamic contrastenhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21:3955-3964 (Pubitemid 46606209)